The Antibody Drug Conjugates Market is gaining remarkable traction as pharmaceutical innovations continue to reshape the landscape of oncology. Antibody-drug conjugates (ADCs) represent a cutting-edge class of biopharmaceuticals that combine the targeting capabilities of monoclonal antibodies with the potent cell-killing ability of cytotoxic drugs. This revolutionary approach to cancer treatment offers targeted drug delivery, reducing side effects and enhancing efficacy making ADCs a game changer in modern medicine. https://wemarketresearch.com/reports/antibody-drug-conjugates-market/132